# NormOxys

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/normoxys

- Industry: Biotechnology
- Headquarters: Wellesley, US
- Website: normoxys.com
- Total disclosed funding: $23M
- Latest round: Series C (May 24, 2010)
- Investors on record: 2

## About

NormOxys Inc. is a biotechnology company focused on developing innovative therapeutic solutions to enhance medical treatment and patient outcomes. Its primary offerings include advanced medical devices and treatment protocols for chronic disease management.NormOxys Inc. operates in the biotechnology sector, concentrating on therapeutic solutions for healthcare challenges. The company, headquartered in Wellesley, US, has undergone strategic pivots to enhance its product offerings. Founded by Claude Nicolau, NormOxys has engaged in 4 funding deals, the latest being a Venture Debt round in November 2011, raising USD 0.6 million, contributing to a total of USD 17.56 mn raised.NormOxys specializes in advanced therapeutic solutions aimed at addressing specific health challenges in the medical field. The core product offerings include a range of innovative medical devices and treatment protocols designed to enhance patient care and improve clinical outcomes. These products serve a diverse client base, including hospitals, outpatient care facilities, and specialized clinics that focus on chronic disease management. NormOxys's services are tailored to meet the needs of healthcare providers and institutions, offering them effective tools to manage complex patient cases. The company markets its products primarily in North America and Europe, catering to the needs of healthcare professionals who require reliable and effective solutions to improve patient health and operational efficiency.NormOxys generates revenue through a structured model that incorporates direct sales to healthcare providers and partnerships with distributors in the medical supply sector. The company typically engages in B2B transactions, providing its products directly to hospitals and clinics while also establishing strategic alliances with key stakeholders in the healthcare ecosystem. Pricing plans are aligned with the value offered by their flagship products, ensuring that clients receive optimal solutions for their investment. The revenue from these transactions is reinforced by ongoing support services that accompany product sales, solidifying long-term relationships with customers and enhancing client retention. By focusing on delivering high-quality products and exceptional service, NormOxys establishes a stable revenue stream from its core offerings in the medical device sector.NormOxys plans to enhance its product line with new medical devices designed to address unmet healthcare needs, with potential launches slated for the upcoming year. The company aims to expand into additional European markets by 2012, leveraging its recent Venture Debt funding of USD 0.6 million to support these initiatives. This strategic expansion is designed to strengthen its market presence and enhance service delivery to healthcare providers.

## Funding rounds

- Series C, May 24, 2010, $18M — Care Capital, Index Ventures
- Series A, Aug 23, 2007, $5.3M — Index Ventures

## Investors

- Index Ventures (https://capitalatlas.ai/funds/index-ventures) — Series A, Series C
- Care Capital (https://capitalatlas.ai/funds/care-capital) — Series C